source
- Axiom Biosciences to launch IPO on Hong Kong exchange before Nasdaq co‑listingSan Diego‑based Axiom Biosciences announced plans to go public with a primary listing on the Hong Kong Stock Exchange, followed later by a Nasdaq co‑listing, a structure it says is a first for a U.…
- FDA’s push to publish complete response letters faces legal uncertainty and possible pauseThe FDA began releasing complete response letters (CRLs) to the public last year, a move promoted as increasing transparency for drug developers, investors, and patients. However, the policy has e…